

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 21-121

CHEMISTRY REVIEW(S)

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS, HFD-120
REVIEW OF CHEMISTRY, MANUFACTURING, AND CONTROLS

NDA 21-121

CHEM REVIEW: #2

REVIEW DATE: 7/15/00

| SUBMISSION TYPE | DOCUMENT DATE | CDER DATE | ASSIGNED DATE |
|-----------------|---------------|-----------|---------------|
| Amendment(AZ) | 6/1/00 | 6/5/00 | 6/7/00 |
| Amendment(BZ) | 6/14/00 | 6/15/00 | 6/22/00 |
| Amendment(BC) | 6/28/00 | 6/29/00 | 7/5/00 |
| Amendment(BL) | 7/7/00 | 7/10/00 | 7/11/00 |

NAME AND ADDRESS OF APPLICANT:

ALZA Corporation
950 Page Mill Road
P.O. Box 10950
Palo Alto, CA 94303-0802

DRUG PRODUCT NAME:

Proprietary: CONCERTA™
Non proprietary/USAN: Methylphenidate hydrochloride
Code Name/Number: OROS®(methylphenidate HCl)
Chem. Type/Ther. Class: 3S

PHARMACOLOGICAL CATEGORY/INDICATION: Attention Deficit Disorder(ADD)/ Attention Deficit Hyperactivity Disorder(ADHD)

DOSAGE FORM: Osmotic Tablet

STRENGTHS: 18mg and 36mg

ROUTE OF ADMINISTRATION: Oral

DISPENSED: RX OTC

SPECIAL PRODUCTS: Yes No

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA:

CA Name: 2-Piperidineacetic acid, α -phenyl-, methyl ester, hydrochloride, (R*,R*)-(±)-


USAN Name: Methylphenidate hydrochloride USP

Chemical Formula: C₁₄H₁₉NO₂ · HCl

Molecular Weight: 269.77

CAS Registry Number: CAS-298-59-9

Laboratory code: None listed



Methods Validation

For FDA Lab



RELATED REVIEW

Office of Clinical Pharmacology
and Biopharmaceutics
(M. Sunzel, Ph.D., I.Mahmood, Ph.D.)
(M. Sunzel, Ph.D., P.Marroum, Ph.D.)

1st review completed 2/10/00
Addendum completed 4/17/00
Recommends: Revised dissolution specifications
are Acceptable; Type A *in-vitro-in vivo* correlation
is Acceptable.

Office of Post-Marketing Drug Risk Assessment
(OPDRA, HFD-400;
OPDRA Consult#: 99-021)

Submitted by HFD-120 under 154,575 on 7/29/99
Recommends: Concerta™ is Acceptable

ONDC, HFD-805(Micro.)
(N. Sweeney, Ph.D.)

Submitted consult on 8/16/99(D.Klein),
Recommends: Approval on 10/5/99.

COMMENTS:


1.



d 5%.

- 3. The proposed 24 month expiration date at 25°C for the 18mg and 36mg tablet in HDPE bottles is acceptable.
- 4. The stability commitments are acceptable.
- 5. The proposed Container Closure Change Protocol is acceptable.
- 6. ALZA has satisfactorily addressed the CMC deficiencies from the 5/18/00 Approvable letter.
- 7. The following CMC sections of the submission are acceptable: Drug Substance specifications; Drug Product Components/Composition; Drug Product Manufacturer; Drug Product Manufacturing and Packaging; Drug Product Specifications; Drug Product Container Closure System; Drug Product Stability; Establishment Inspection; Package Insert and Labeling.

8.



CONCLUSIONS: Recommend Approval of the CMC section of N21-121. Refer to the draft letter.

Donald N. Klein, Ph.D.
Review Chemist, HFD-120

7/15/00

Robert H. Seevers, Ph.D.
Chemistry Team Leader, HFD-120

7/17/00

NDA 21-121(AZ)

CONCERTA Tablets, ALZA

cc:

Orig. NDA 21-121
HFD-120/Division File
HFD-810/JSimmons
HFD-810/HPatel
HFD-120/DKlein
HFD-120/RSeEVERS
HFD-120/AMosholder
HFD-120/AMHomonnay
HFD-120/BRosloff
HFD-860/MSunzel
HFD-860/IMahmood
File: _____

**APPEARS THIS WAY
ON ORIGINAL**

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS, HFD-120
REVIEW OF CHEMISTRY, MANUFACTURING, AND CONTROLS

NDA 21-121

CHEM REVIEW: #1

REVIEW DATE: 5/10/00

| SUBMISSION TYPE | DOCUMENT DATE | CDER DATE | ASSIGNED DATE |
|-----------------|---------------|-----------|---------------|
| ORIGINAL | 7/15/99 | 7/19/99 | 7/21/99 |
| AMENDMENT N(BC) | 1/31/00 | 2/2/00 | 2/4/00 |
| AMENDMENT N(SU) | 2/15/00 | 2/16/00 | 2/17/00 |
| AMENDMENT N(BZ) | 3/29/00 | 3/30/00 | 4/5/00 |
| AMENDMENT N(BC) | 4/3/00 | 4/4/00 | 4/5/00 |
| AMENDMENT N(BB) | 4/4/00 | 4/5/00 | 4/10/00 |
| AMENDMENT N(BC) | 4/20/00 | 4/21/00 | 4/26/00 |

NAME AND ADDRESS OF APPLICANT:

ALZA Corporation
950 Page Mill Road
P.O. Box 10950
Palo Alto, CA 94303-0802

DRUG PRODUCT NAME:

Proprietary: CONCERTA™
Non proprietary/USAN: Methylphenidate hydrochloride
Code Name/Number: OROS®(methylphenidate HCl)
Chem. Type/Ther. Class: 3S

PHARMACOLOGICAL CATEGORY/INDICATION: Attention Deficit Disorder(ADD)/ Attention Deficit Hyperactivity Disorder(ADHD)

DOSAGE FORM: Osmotic Tablet

STRENGTHS: 18mg and 36mg

ROUTE OF ADMINISTRATION: Oral

DISPENSED: RX OTC

SPECIAL PRODUCTS: Yes No

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA:


CA Name: 2-Piperidineacetic acid, α -phenyl-, methyl ester, hydrochloride, (R*,R*)(±)-
USAN Name: Methylphenidate hydrochloride USP

Chemical Formula: $C_{14}H_{19}NO_2 \cdot HCl$

Molecular Weight: 269.77

CAS Registry Number: CAS-298-59-9

Laboratory code: None listed



Methods Validation Pending



RELATED REVIEW

Office of Clinical Pharmacology
and Biopharmaceutics
(M. Sunzel, Ph.D., I.Mahmood, Ph.D.)
(M. Sunzel, Ph.D., P.Marroum, Ph.D.)

1st review completed 2/10/00
Addendum completed 4/17/00
Recommends: Revised dissolution specifications
are Acceptable; Type A *in-vitro-in vivo* correlation
is Acceptable.

Office of Post-Marketing Drug Risk Assessment
(OPDRA, HFD-400;
OPDRA Consult#: 99-021)


Submitted by HFD-120 under 154,575 on 7/29/99
Recommends: Concerta™ is Acceptable

ONDC, HFD-805(Micro.)
(N. Sweeney, Ph.D.)


Submitted consult on 8/16/99(D.Klein),
Recommends: Approval on 10/5/99.

COMMENTS:


- 1. The following CMC sections of the submission are acceptable: Drug Product Specifications & Methods for Inactive Components; Drug Product Microbiology; Environmental Assessment; Investigational Formulation.
- The following CMC sections of the submission are approvable: Drug Substance specifications proposed by ALZA; Drug Product Components/Composition; Drug Product Manufacturer; Drug Product Manufacturing and Packaging; Drug Product Specifications; Drug Product Container Closure System; Drug Product Stability; Establishment Inspection; Package Insert and Labeling.



CONCLUSIONS: For the CMC section of the submission, I recommend Approvable. Refer to the list of deficiencies at the end of the review.

 5/14/00

Donald N. Klein, Ph.D.
Review/Chemistry HFD-120

 5/11/00

Robert Seevers, Ph.D.
Chemistry Team Leader, HFD-120

NDA 21-121

CONCERTA Tablets, ALZA

cc:

Orig. NDA 21-121
HFD-120/Division File
HFD-810/JSimmons
HFD-810/HPatel
HFD-120/DKlein
HFD-120/RSeevers
HFD-120/AMosholder
HFD-120/AMHomonnay
HFD-120/BRosloff
HFD-860/MSunzel
HFD-860/IMahmood
File: - _____

**APPEARS THIS WAY
ON ORIGINAL**